دورية أكاديمية
أعرض في EDS

Therapeutic Effects of Essential Oils and Their Bioactive Compounds on Prostate Cancer Treatment.

التفاصيل البيبلوغرافية
العنوان: Therapeutic Effects of Essential Oils and Their Bioactive Compounds on Prostate Cancer Treatment.
المؤلفون: Pimentel LS; Laboratory of Nanobiotechnology Professor Luiz Ricardo Goulart Filho, Institute of Biotechnology, Federal University of Uberlândia, Campus Umuarama, Bloco 2E, Sala 248, Uberlândia 38405-302, MG, Brazil., Bastos LM; Laboratory of Nanobiotechnology Professor Luiz Ricardo Goulart Filho, Institute of Biotechnology, Federal University of Uberlândia, Campus Umuarama, Bloco 2E, Sala 248, Uberlândia 38405-302, MG, Brazil., Goulart LR; Laboratory of Nanobiotechnology Professor Luiz Ricardo Goulart Filho, Institute of Biotechnology, Federal University of Uberlândia, Campus Umuarama, Bloco 2E, Sala 248, Uberlândia 38405-302, MG, Brazil., Ribeiro LNM; Laboratory of Nanobiotechnology Professor Luiz Ricardo Goulart Filho, Institute of Biotechnology, Federal University of Uberlândia, Campus Umuarama, Bloco 2E, Sala 248, Uberlândia 38405-302, MG, Brazil.
المصدر: Pharmaceutics [Pharmaceutics] 2024 Apr 24; Vol. 16 (5). Date of Electronic Publication: 2024 Apr 24.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Since prostate cancer (PCa) relies on limited therapies, more effective alternatives are required. Essential oils (EOs) and their bioactive compounds are natural products that have many properties including anticancer activity. This review covers studies published between 2000 and 2023 and discusses the anti-prostate cancer mechanisms of the EOs from several plant species and their main bioactive compounds. It also provides a critical perspective regarding the challenges to be overcome until they reach the market. EOs from chamomile, cinnamon, Citrus species, turmeric, Cymbopogon species, ginger, lavender, Mentha species, rosemary, Salvia species, thyme and other species have been tested in different PCa cell lines and have shown excellent results, including the inhibition of cell growth and migration, the induction of apoptosis, modulation in the expression of apoptotic and anti-apoptotic genes and the suppression of angiogenesis. The most challenging aspects of EOs, which limit their clinical uses, are their highly lipophilic nature, physicochemical instability, photosensitivity, high volatility and composition variability. The processing of EO-based products in the pharmaceutical field may be an interesting alternative to circumvent EOs' limitations, resulting in several benefits in their further clinical use. Identifying their bioactive compounds, therapeutic effects and chemical structures could open new perspectives for innovative developments in the field. Moreover, this could be helpful in obtaining versatile chemical synthesis routes and/or biotechnological drug production strategies, providing an accurate, safe and sustainable source of these bioactive compounds, while looking at their use as gold-standard therapy in the close future.
References: Nat Prod Res. 2016;30(9):1088-92. (PMID: 26586465)
Trends Genet. 2001 Sep;17(9):536-40. (PMID: 11525837)
Molecules. 2021 Oct 12;26(20):. (PMID: 34684723)
Foods. 2021 Dec 18;10(12):. (PMID: 34945695)
Asian Pac J Cancer Prev. 2011;12(8):1989-93. (PMID: 22292639)
Mol Med Rep. 2010 Nov 1;3(6):895-901. (PMID: 21132119)
Cells. 2019 Jan 20;8(1):. (PMID: 30669516)
Chem Biodivers. 2024 Feb;21(2):e202301535. (PMID: 38010960)
Bioresour Technol. 2010 Jun;101(11):4205-11. (PMID: 20133123)
J Agric Food Chem. 2007 Nov 14;55(23):9470-8. (PMID: 17939735)
Cancer Res. 1977 Nov;37(11):4049-58. (PMID: 908039)
Drug Resist Updat. 2002 Dec;5(6):234-48. (PMID: 12531180)
PLoS One. 2014 Mar 05;9(3):e89772. (PMID: 24598693)
Phytother Res. 2002 Jun;16(4):301-8. (PMID: 12112282)
J Hematol Oncol. 2021 Mar 29;14(1):51. (PMID: 33781305)
J Clin Biochem Nutr. 2009 Mar;44(2):125-30. (PMID: 19308266)
World J Oncol. 2019 Apr;10(2):63-89. (PMID: 31068988)
In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9. (PMID: 10462204)
Cancer Res. 1994 May 15;54(10):2577-81. (PMID: 8168083)
Planta Med. 2012 Jun;78(10):974-80. (PMID: 22673830)
Molecules. 2020 Sep 12;25(18):. (PMID: 32932678)
Mini Rev Med Chem. 2020;20(11):958-974. (PMID: 31969098)
Int J Mol Sci. 2018 Jul 05;19(7):. (PMID: 29976894)
Br J Nutr. 2012 Feb;107(4):473-84. (PMID: 21849094)
Pathol Oncol Res. 2012 Oct;18(4):903-10. (PMID: 22437241)
Nat Prod Res. 2021 Mar;35(5):782-787. (PMID: 30938173)
Asian Pac J Cancer Prev. 2016;17(S3):125-30. (PMID: 27165249)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Lipids Health Dis. 2017 Aug 3;16(1):146. (PMID: 28774297)
Bioinorg Chem Appl. 2022 May 26;2022:9569226. (PMID: 35662912)
J Sci Food Agric. 2013 Dec;93(15):3643-53. (PMID: 23765679)
Chemotherapy. 2018;63(1):1-7. (PMID: 29069647)
Anticancer Res. 2007 Sep-Oct;27(5A):3293-9. (PMID: 17970073)
Z Naturforsch C J Biosci. 2002 Sep-Oct;57(9-10):797-800. (PMID: 12440714)
J Ethnopharmacol. 2023 Dec 5;317:116835. (PMID: 37355085)
Oncol Lett. 2020 Dec;20(6):289. (PMID: 33029205)
J Pharm Pharmacol. 2010 Aug;62(8):1018-27. (PMID: 20663036)
Oncogene. 2020 Dec;39(50):7225-7238. (PMID: 33046797)
Molecules. 2020 Jan 05;25(1):. (PMID: 31948058)
Med Oncol. 2020 Sep 22;37(10):91. (PMID: 32960365)
Int J Prev Med. 2019 Oct 09;10:156. (PMID: 32133074)
Biomed Res Int. 2014;2014:154106. (PMID: 25003106)
Biomed Pharmacother. 2020 Nov;131:110717. (PMID: 33152908)
Curr Issues Mol Biol. 2021 Aug 28;43(2):996-1018. (PMID: 34563040)
J Med Life. 2014;7 Spec No. 3:56-60. (PMID: 25870697)
J Ethnopharmacol. 2023 Mar 1;303:115929. (PMID: 36379416)
Onkologie. 2013;36(10):592-6. (PMID: 24107915)
Plants (Basel). 2020 Dec 28;10(1):. (PMID: 33379197)
Phytochemistry. 2008 Feb;69(4):919-27. (PMID: 18177907)
Drug Des Devel Ther. 2020 Aug 18;14:3363-3372. (PMID: 32884240)
Dermatitis. 2016 Mar-Apr;27(2):39-42. (PMID: 26983089)
Plants (Basel). 2021 Apr 06;10(4):. (PMID: 33917630)
Asian Pac J Cancer Prev. 2022 Apr 01;23(4):1215-1222. (PMID: 35485678)
Chem Biodivers. 2018 Nov;15(11):e1800354. (PMID: 30187618)
Nutrients. 2016 Aug 12;8(8):. (PMID: 27529277)
Redox Biol. 2018 Apr;14:439-449. (PMID: 29078169)
Nutrients. 2018 Sep 01;10(9):. (PMID: 30200410)
Nat Prod Res. 2013;27(10):862-8. (PMID: 22480321)
Food Chem. 2013 Nov 1;141(1):196-200. (PMID: 23768347)
Biomed Res Int. 2022 May 24;2022:6317201. (PMID: 35655488)
J Carcinog. 2009;8:9. (PMID: 19465777)
Z Naturforsch C J Biosci. 2020 Nov 23;76(5-6):175-185. (PMID: 33909955)
J Med Food. 2013 Jan;16(1):20-5. (PMID: 23297712)
Curr Drug Metab. 2018;19(13):1100-1110. (PMID: 30039757)
Invest Urol. 1979 Jul;17(1):16-23. (PMID: 447482)
Phytother Res. 2021 Oct;35(10):5781-5794. (PMID: 34363252)
Molecules. 2020 Dec 30;26(1):. (PMID: 33396666)
Int J Mol Sci. 2018 Jan 19;19(1):. (PMID: 29351194)
Cells. 2021 Jun 11;10(6):. (PMID: 34208346)
Anticancer Agents Med Chem. 2019;19(13):1588-1608. (PMID: 31364516)
Endocr Connect. 2017 Nov;6(8):R146-R161. (PMID: 29030409)
Medicines (Basel). 2015 Dec 21;2(4):340-349. (PMID: 28930216)
Cancer Res. 1984 Aug;44(8):3522-9. (PMID: 6744277)
Front Oncol. 2019 Sep 04;9:858. (PMID: 31552182)
Molecules. 2020 Sep 09;25(18):. (PMID: 32917001)
J Sci Food Agric. 2010 Aug 30;90(11):1827-36. (PMID: 20602517)
Prog Clin Biol Res. 1980;37:115-32. (PMID: 7384082)
Chem Biodivers. 2023 Oct;20(10):e202300291. (PMID: 37699128)
Dermatitis. 2016 Mar-Apr;27(2):43-9. (PMID: 26983090)
Oncologist. 2021 Jan;26(1):e115-e129. (PMID: 32790034)
Pak J Biol Sci. 2020 Jan;23(9):1184-1192. (PMID: 32981249)
Biochim Biophys Acta. 2009 Jan;1792(1):33-8. (PMID: 18955132)
Toxicol Mech Methods. 2021 Feb;31(2):100-106. (PMID: 33054537)
J Infect Dev Ctries. 2020 Feb 29;14(2):177-183. (PMID: 32146452)
Molecules. 2023 Jun 05;28(11):. (PMID: 37299034)
Food Chem Toxicol. 2007 May;45(5):683-90. (PMID: 17175086)
Plants (Basel). 2021 Dec 23;11(1):. (PMID: 35009033)
Pharm Biol. 2012 Apr;50(4):474-80. (PMID: 22136358)
Oxid Med Cell Longev. 2016;2016:1469693. (PMID: 27803760)
IUBMB Life. 2018 May;70(5):445-457. (PMID: 29537730)
Heliyon. 2023 Feb 17;9(3):e13807. (PMID: 36873474)
Curr Opin Urol. 2016 May;26(3):213-8. (PMID: 26986650)
Food Chem Toxicol. 2019 Mar;125:198-209. (PMID: 30615955)
Integr Cancer Ther. 2017 Jun;16(2):215-226. (PMID: 27151584)
Cancer Lett. 2011 Dec 22;312(2):178-88. (PMID: 21924548)
Int J Oncol. 2012 May;40(5):1683-90. (PMID: 22200837)
Life (Basel). 2022 Mar 25;12(4):. (PMID: 35454969)
Plants (Basel). 2022 Jul 07;11(14):. (PMID: 35890431)
Molecules. 2017 Aug 22;22(8):. (PMID: 28829378)
Biomed Res Int. 2020 Mar 18;2020:6040727. (PMID: 32258129)
Int J Mol Sci. 2021 Nov 09;22(22):. (PMID: 34830022)
Chem Biodivers. 2013 Apr;10(4):722-9. (PMID: 23576358)
Plants (Basel). 2023 Mar 13;12(6):. (PMID: 36986980)
Planta Med. 2003 May;69(5):402-7. (PMID: 12802719)
Cancer Med. 2016 Oct;5(10):2899-2908. (PMID: 27683099)
Braz J Microbiol. 2010 Oct;41(4):1070-8. (PMID: 24031588)
Yale J Biol Med. 2020 Jun 29;93(2):291-305. (PMID: 32607090)
J Tradit Complement Med. 2018 Sep 28;11(2):75-81. (PMID: 33728265)
Molecules. 2010 Apr 30;15(5):3200-10. (PMID: 20657472)
Mol Carcinog. 2014 Oct;53(10):793-806. (PMID: 23765383)
Int J Pharm. 2015 Apr 10;483(1-2):220-43. (PMID: 25683145)
Molecules. 2022 Jul 08;27(14):. (PMID: 35889245)
Bratisl Lek Listy. 2020;121(2):122-128. (PMID: 32115964)
BMC Complement Altern Med. 2013 Oct 22;13:275. (PMID: 24148965)
Biomol Concepts. 2020 Apr 15;11(1):86-96. (PMID: 32304294)
Phytother Res. 2018 Sep;32(9):1688-1706. (PMID: 29785774)
Chem Biodivers. 2019 Oct;16(10):e1900374. (PMID: 31441194)
Anticancer Agents Med Chem. 2018;18(13):1815-1827. (PMID: 30277165)
Food Chem Toxicol. 2008 Feb;46(2):446-75. (PMID: 17996351)
Dermatitis. 2016 Nov/Dec;27(6):325-332. (PMID: 27775966)
Molecules. 2022 Jul 28;27(15):. (PMID: 35956786)
Pharmaceutics. 2023 Oct 15;15(10):. (PMID: 37896230)
Nutr Cancer. 2017 Oct;69(7):1075-1087. (PMID: 28872904)
Clin Sci (Lond). 2017 Feb 1;131(3):197-210. (PMID: 28057891)
Complement Ther Clin Pract. 2021 Feb;42:101286. (PMID: 33340989)
Plants (Basel). 2021 Sep 06;10(9):. (PMID: 34579380)
Front Pharmacol. 2022 Aug 29;13:997918. (PMID: 36105217)
Int J Cancer. 1994 May 1;57(3):406-12. (PMID: 8169003)
Biochimie. 2018 Oct;153:162-170. (PMID: 29501481)
Biochem Biophys Res Commun. 2011 Apr 1;407(1):129-34. (PMID: 21371438)
PLoS One. 2014 Mar 24;9(3):e92122. (PMID: 24662935)
فهرسة مساهمة: Keywords: essential oil; natural products; natural treatment; prostate cancer
تواريخ الأحداث: Date Created: 20240525 Latest Revision: 20240527
رمز التحديث: 20240527
مُعرف محوري في PubMed: PMC11125265
DOI: 10.3390/pharmaceutics16050583
PMID: 38794244
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics16050583